Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na-Reference-Cited by-同舟云学术

Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na

Published:2012-08 Issue:8 Volume:36 Page:982-989
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Olnes Matthew J.,Shenoy Aarthie,Weinstein Barbara,Pfannes Loretta,Loeliger Kelsey,Tucker Zachary,Tian Xin,Kwak Minjung,Wilhelm Francois,Yong Agnes S.M.,Maric Irina,Maniar Manoj,Scheinberg Phillip,Groopman Jerome,Young Neal S.,Sloand Elaine M.

Funder

Intramural Research Program of the NIH, National Heart, Lung and Blood Institute

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference31 articles.

1. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

2. Myelodysplastic syndromes: incidence and survival in the United States;Ma;Cancer,2007

3. Myelodysplastic syndromes;Nimer;Blood,2008

4. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

5. Efficacy of lenalidomide in myelodysplastic syndromes;List;N Engl J Med,2005

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na);Pharmaceutics;2023-04-13

2. In the Pipeline: Emerging Therapy for MDS and MDS/MPN;Pathogenesis and Treatment of Leukemia;2023

3. Synthesis and antitumor effects of novel benzyl naphthyl sulfoxide/sulfone derivatives derived from Rigosertib;RSC Advances;2021

4. Targeting the Microenvironment in MDS: The Final Frontier;Frontiers in Pharmacology;2020-07-09

5. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes;Annals of Hematology;2019-07-16